Thiazolidinediones (TZDs), which are used to treat type 2 diabetes mellitus, are associated with a 1.3-fold elevation in risk for osteoporotic fracture compared with other antidiabetic medications, according to a report published online March 6 in Pharmacoepidemiology and Drug Safety.Another double whammy for fatsos - diabetes and osteoporosis from the meds taken to treat a disease of choice.
Two randomized controlled clinical trials implicated TZDs in decreased bone density in the hip and lumbar spine in women, and a meta-analysis of 10 studies found increased risk for fracture in the upper arm, hand, and foot.
TZDs decrease bone mineral density by activating peroxisome proliferator–activated receptors, which shifts the fates of mesenchymal stem cells in bone marrow toward the adipocyte lineage and away from producing osteoblasts. Diabetes can also affect bone remodeling by altering vitamin D metabolism, glycosylating collagen, and increasing output of calcium in urine.
They should be paying for all this themselves.
Period.
Posts
No comments:
Post a Comment